Patents by Inventor Jeffrey Milbrandt
Jeffrey Milbrandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11903935Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.Type: GrantFiled: October 22, 2021Date of Patent: February 20, 2024Assignees: Washington University, Disarm Therapeutics, Inc.Inventors: Jeffrey Milbrandt, Kow Essuman, Yo Sasaki, Aaron Diantonio, Xianrong Mao, Rajesh Devraj, Raul Eduardo Krauss, Robert Owen Hughes
-
Publication number: 20230227808Abstract: A sample containing particles having high-molecular-weight (HMW) DNA is entrapped in a gel matrix, and the gel matrix is exposed to a lysis reagent configured to release the HMW DNA from the particles. The HMW DNA may be purified by subjecting the gel matrix to an electrophoretic field that removes the HMW DNA from the particles, lysis reagents, and/or other sample constituents, from the gel matrix such that the HMW DNA remains. The gel matrix may be subjected with DNA cleavase re-agents configured to cleave at specific DNA sequences within the HMW DNA to liberate defined segments of the DNA as fragments of reduced size. The gel matrix may also be subjected to an electrophoretic field, which moves and separates the DNA fragments from uncleaved DNA of the HMW DNA, which remains substantially immobile. The electrophoretically separated DNA fragments may be isolated from the gel matrix.Type: ApplicationFiled: January 3, 2023Publication date: July 20, 2023Applicants: Sage Science, Inc., Washington UniversityInventors: Robi David Mitra, Jeffrey MILBRANDT, Ezra Solomon ABRAMS, Todd J. BARBERA, T. Christian BOLES
-
Patent number: 11542495Abstract: A sample containing particles having high-molecular-weight (HMW) DNA is entrapped in a gel matrix, and the gel matrix is exposed to a lysis reagent configured to release the HMW DNA from the particles. The HMW DNA may be purified by subjecting the gel matrix to an electrophoretic field that removes the HMW DNA from the particles, lysis reagents, and/or other sample constituents, from the gel matrix such that the HMW DNA remains. The gel matrix may be subjected with DNA cleavase reagents configured to cleave at specific DNA sequences within the HMW DNA to liberate defined segments of the DNA as fragments of reduced size. The gel matrix may also be subjected to an electrophoretic field, which moves and separates the DNA fragments from uncleaved DNA of the HMW DNA, which remains substantially immobile. The electrophoretically separated DNA fragments may be isolated from the gel matrix.Type: GrantFiled: November 21, 2016Date of Patent: January 3, 2023Assignees: Sage Science, Inc., Washington UniversityInventors: Robi David Mitra, Jeffrey Milbrandt, Ezra Solomon Abrams, Todd J. Barbera, T. Christian Boles
-
Publication number: 20220409648Abstract: Among the various aspects of the present disclosure is the provision is the provision of a SARM1 activating agent or prodrug thereof and methods of using same.Type: ApplicationFiled: June 28, 2022Publication date: December 29, 2022Inventors: Jeffrey Milbrandt, Aaron DiAntonio, Tong Wu, Amy Strickland, Adam Bloom, Yo Sasaki, Jian Zhu, Yurie Yamada
-
Patent number: 11253503Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.Type: GrantFiled: September 22, 2017Date of Patent: February 22, 2022Assignees: Washington University, Disarm Therapeutics, Inc.Inventors: Jeffrey Milbrandt, Kow Essuman, Yo Sasaki, Aaron DiAntonio, Xianrong Mao, Rajesh Devraj, Raul Eduardo Krauss, Robert Owen Hughes
-
Publication number: 20220040164Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.Type: ApplicationFiled: October 22, 2021Publication date: February 10, 2022Inventors: Jeffrey MILBRANDT, Kow Essuman, Yo Sasaki, Aaron Diantonio, Xianrong Mao, Rajesh Devraj, Raul Eduardo Krauss, Robert Owen Hughes
-
Publication number: 20210207122Abstract: A sample containing particles having high-molecular-weight (HMW) DNA is entrapped in a gel matrix, and the gel matrix is exposed to a lysis reagent configured to release the HMW DNA from the particles. The HMW DNA may be purified by subjecting the gel matrix to an electrophoretic field that removes the HMW DNA from the particles, lysis reagents, and/or other sample constituents, from the gel matrix such that the HMW DNA remains. The gel matrix may be subjected with DNA cleavase reagents configured to cleave at specific DNA sequences within the HMW DNA to liberate defined segments of the DNA as fragments of reduced size. The gel matrix may also be subjected to an electrophoretic field, which moves and separates the DNA fragments from uncleaved DNA of the HMW DNA, which remains substantially immobile. The electrophoretically separated DNA fragments may be isolated from the gel matrix.Type: ApplicationFiled: November 21, 2016Publication date: July 8, 2021Applicants: Sage Science, Inc., Washington UniversityInventors: Robi David MITRA, Jeffrey MILBRANDT, Ezra Solomon ABRAMS, Todd J. BARBERA, T. Christian BOLES
-
Publication number: 20200129493Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.Type: ApplicationFiled: September 22, 2017Publication date: April 30, 2020Applicants: Washington University, Disarm Therapeutics, Inc.Inventors: Jeffrey MILBRANDT, Kow ESSUMAN, Yo SASAKI, Aaron DIANTONIO, Xianrong MAO, Rajesh DEVRAJ, Raul Eduardo KRAUSS, Robert Owen HUGHES
-
Publication number: 20160367497Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuin AMPK activity, LKB1 activity and/or CaMKK? activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Inventors: Jeffrey Milbrandt, Biplab Dasgupta
-
Publication number: 20160199401Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: ApplicationFiled: March 11, 2016Publication date: July 14, 2016Inventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki
-
Patent number: 9295688Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: GrantFiled: October 10, 2014Date of Patent: March 29, 2016Assignee: Washington UniversityInventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki
-
Publication number: 20150038560Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: ApplicationFiled: October 10, 2014Publication date: February 5, 2015Applicant: WASHINGTON UNIVERSITYInventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki
-
Patent number: 8889126Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: GrantFiled: May 28, 2010Date of Patent: November 18, 2014Assignee: Washington UniversityInventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki
-
Publication number: 20140011890Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuin AMPK activity, LKB1 activity and/or CaMKK? activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.Type: ApplicationFiled: July 26, 2013Publication date: January 9, 2014Applicant: WASHINGTON UNIVERSITYInventors: Jeffrey Milbrandt, Biplab Dasgupta
-
Patent number: 8133685Abstract: Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity.Type: GrantFiled: April 3, 2009Date of Patent: March 13, 2012Assignee: Washington UniversityInventors: Jeffrey Milbrandt, Biplab Dasgupta
-
Publication number: 20100272702Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: ApplicationFiled: May 28, 2010Publication date: October 28, 2010Applicant: WASHINGTON UNIVERSITYInventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki
-
Publication number: 20100221748Abstract: Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity.Type: ApplicationFiled: April 3, 2009Publication date: September 2, 2010Applicant: Washington UniversityInventors: Jeffrey Milbrandt, Biplab Dasgupta
-
Patent number: 7776326Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: GrantFiled: June 3, 2005Date of Patent: August 17, 2010Assignee: Washington UniversityInventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki
-
Publication number: 20100047177Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuinAMPK activity, LKB 1 activity and/or CaMKK? activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.Type: ApplicationFiled: January 28, 2008Publication date: February 25, 2010Applicant: WASHINGTON UNIVERSITYInventors: Jeffrey Milbrandt, Biplab Dasgupta
-
Publication number: 20060002914Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.Type: ApplicationFiled: June 3, 2005Publication date: January 5, 2006Inventors: Jeffrey Milbrandt, Toshiyuki Araki, Yo Sasaki